Acme United Earnings Call: Growth Up, Margins Squeezed

Acme United Corporation. ((ACU)) has held its Q1 earnings call. Read on for the main highlights of the call.

Acme United’s latest earnings call painted a picture of a company growing briskly on the top line while wrestling with near‑term margin and cash pressures. Management balanced upbeat commentary on double‑digit sales gains, acquisitions, and automation against candid discussion of tariff‑driven cost spikes, higher SG&A, and temporary quality‑related spending that together dragged down profitability and increased leverage.

Revenue Growth Accelerates Despite Mixed Profit Picture

Net sales climbed 14% year over year to $52.3 million, underscoring solid demand across the portfolio. Even excluding the newly acquired MyMedic direct‑to‑consumer business, revenues were up 6%, signaling that underlying growth remains intact despite macro and cost headwinds.

Europe and Canada Deliver Standout Regional Gains

Europe posted a 19% sales increase in local currency to about €4.0 million, fueled by strong demand for cutting and sharpening tools and a record quarter in first‑aid products. Canada also delivered double‑digit growth, with management citing roughly 11% local‑currency and up to 16% overall gains, led largely by first‑aid offerings.

Gross Margin Benefits From DTC Mix Shift

Reported gross margin ticked up to 39.7% from 39.0% a year earlier, aided by the higher‑margin profile of the MyMedic business, which represented roughly 8% of sales. This improvement masked pressure in the legacy portfolio but highlighted how mix toward direct‑to‑consumer channels can cushion profitability.

Acquisitions Build DTC Muscle and Brand Reach

The company closed the MyMedic acquisition and a small German direct‑to‑consumer operation that is already outperforming expectations. MyMedic brings about 500,000 social media followers and in‑house expertise in video content and paid advertising, which management plans to leverage to drive digital sales across other product lines.

Spill Magic Facility Move Underpins Rapid Growth

Acme completed its move into a new Spill Magic facility in Mount Pleasant, Tennessee, previously purchased for about $6 million. Production is underway, orders are strong, and management reported roughly 30% growth for Spill Magic in the quarter, signaling that added capacity is being put to immediate use.

Automation Investments Target Multi‑Year Productivity

The company is ramping up robotics and automation, including automated packaging for BZK wipes and Spill Magic powder and robotics for warehouse cleaning and cycle counting. With planned 2026 capex of about $7 million, these projects are framed as multi‑year productivity drivers that should lower unit costs and support margin expansion.

Integration and Cross‑Selling to Unlock Synergies

Management highlighted ongoing efforts to integrate recent acquisitions by consolidating purchasing, trimming duplicate expenses, and broadening distribution. Plans include expanding MyMedic products into Canadian retail channels, with the aim of boosting sales while improving margins through scale and shared infrastructure.

Free Cash Flow Healthy Before Large One‑Off Outlays

Over the twelve months ended March 31, 2026, Acme generated about $14.2 million of free cash flow before the Tennessee facility purchase. This performance suggests the business can produce solid cash even as it steps up investment, although recent spending has temporarily soaked up liquidity.

Profitability Hit by Tariffs and Incremental Costs

Net income fell roughly 40% year over year to about $1.0 million, or $0.24 per diluted share, compared with $0.41 a year earlier. Management attributed the decline largely to higher tariff‑driven costs and other incremental expenses, offsetting the benefit from higher revenues and mix improvements.

Legacy Gross Margins Squeezed by Tariffs

While the consolidated gross margin looked stable to slightly higher, the core legacy business saw margins compress by roughly 200 basis points. Elevated tariffs and higher input costs were the main culprits, underscoring how headline figures can conceal underlying cost pressure in traditional product lines.

Tariff Shock and Inventory Build Weigh on Q1

Tariff‑related cost increases were capitalized into inventory and flowed through Q1 cost of goods sold, creating an outsized one‑quarter hit. The company also bought about $10 million in additional inventory to hedge against geopolitical risks, a move that inflated working capital but was presented as a risk‑management measure.

Higher SG&A From DTC and Marketing Spend

SG&A expenses climbed to $19.0 million, or 36% of net sales, up from $15.5 million and 34% a year ago. The jump reflects the addition of MyMedic and heavier advertising needed for a direct‑to‑consumer model, though management is targeting SG&A closer to 33% of revenues for the full year as scale and efficiencies build.

Leverage Rises as Cash Funds Deals and Facilities

Net debt increased to $38.6 million from $27.2 million a year earlier, driven by acquisition spending and facility investments. The company also returned roughly $2.4 million to shareholders via dividends and funded its $6 million Tennessee manufacturing and distribution facility, pushing balance‑sheet leverage higher.

MedNap QA Upgrades Add One‑Time Cost Burden

Following an FDA inspection at MedNap, Acme spent roughly $1.25 million to $1.3 million on quality assurance remediation, including consulting, lab enhancements, and equipment upgrades. Management said the project is about 75% complete and characterized much of the spending as non‑recurring, though it weighed on current‑period earnings.

Cutting Segment Feels Promotional and Tariff Drag

The Westcott cutting business came under pressure from promotional disruptions linked to earlier tariff changes, creating choppy year‑over‑year comparisons. Management expects easier comparisons later in the year and signs of gradual recovery, but acknowledged that 2025 and early 2026 have been challenging for this segment.

Guidance: Tariff Pain Fading, Margins Seen Normalizing

Looking ahead, management expects tariff headwinds to ease over the next three quarters as high‑cost inventory is sold through, with margins anticipated to look more normal by Q3. They are also aiming to bring SG&A down toward about 33% of sales while continuing roughly $7 million of capex and focused automation spending designed to improve productivity and support growth.

Acme United’s earnings call underscored a classic trade‑off: aggressive investment for future growth against near‑term margin compression and higher leverage. With tariffs set to moderate and integration, automation, and DTC initiatives ramping, the company is positioned for margin recovery, but investors will be watching execution on cost control and debt management closely in coming quarters.